Private Equity Round in 2022
MISSION is the first and only line of Athlete-Engineered products designed to enhance performance intraining and competition. Launched in 2009, MISSION Athletecare has quickly become a driving force of innovation in the sports industry uniquely focused on products that help athletes prepare, perform and rehab from competition.
Private Equity Round in 2021
Coop Home Goods is a manufacturer of bedding products focused on enhancing the sleeping experience. The company specializes in adjustable pillows designed to accommodate various body types and sleep positions, allowing users to customize the fill for optimal alignment and comfort. In addition to pillows, Coop offers a range of products including comforters, mattress pads, bedding sets, pet beds, and various types of support and throw pillows. The materials used in their products are breathable, promoting proper airflow and contributing to a comfortable sleep environment. Customer inquiries are addressed through multiple channels, including phone, email, and online applications.
Private Equity Round in 2021
SportPet is an established manufacturer and marketer of pet products, specializing in both branded and private label offerings. The company produces a range of items aimed at enhancing the comfort and well-being of pets, including elevated dog beds, deluxe mattress beds, cat carriers, and luxury sofa beds. Additionally, SportPet designs and sells various pet furniture, scratchers, and toys. Committed to quality and safety, SportPet emphasizes environmentally responsible manufacturing practices in its product lines.
reCommerce is a full-service brand agency that assists international brands in optimizing their Amazon presence and increasing sales.
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.
PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies targeting p53 mutations in cancer. The company's lead candidate, PC14586, aims to correct and restore the function of p53, a critical tumor suppressor protein. In addition to this product, PMV Pharmaceuticals is also working on therapies for specific p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, the company leverages over three decades of expertise in p53 biology, aiming to develop first-in-class modulators that could improve treatment outcomes for cancer patients.
Japonesque LLC, founded in 1984 and based in San Ramon, California, specializes in beauty care products tailored for makeup artists and beauty professionals. The company offers a diverse range of items, including cosmetics, eyelash curlers, makeup brushes, nail clippers, and skincare products. Drawing inspiration from the professional makeup tools used in Kabuki theater, Japonesque has developed a collection that emphasizes high-impact color and professional performance. Its products are distributed through retailers across the United States and are also available in beauty supply stores, salons, and spas worldwide. With a commitment to quality and artistry, Japonesque aims to provide essential beauty tools and accessories for discerning makeup enthusiasts.
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.
Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.
Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for cancer and other serious conditions. Its lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, PT2977 is being tested in various combinations and settings, including von Hippel-Lindau disease associated renal cell carcinoma and glioblastoma multiforme. The company is also working on PT2567, another HIF-2a inhibitor in preclinical development targeting non-oncology conditions such as pulmonary arterial hypertension. Founded in 2010 by Steven L. McKnight and supported by the Cancer Prevention Research Institute of Texas and experienced investors, Peloton aims to leverage its scientific collaborations and robust pipeline to establish itself as a leading biotech firm in cancer drug discovery and development.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.
Bear Down Brands is a network of consumer brands that each focus on premium home, health, and personal care products.Bear Down Brands mission is to create elegant, practical, and innovative products that enhance the way you care for yourself and the world around you.Bear Down's focus has been on developing a well-rounded product portfolio while providing advanced product technologies, award-winning customer support, and strong brand relationships with our consumers.
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.
Hubble is a mobile application designed to facilitate connections among local individuals with shared interests. By leveraging a location-based questions and answers format, the app allows users to pose inquiries to nearby individuals, fostering community engagement and enabling meaningful conversations beyond typical meetups. This innovative platform helps users access hyperlocal information efficiently, eliminating the need to sift through various reviews and websites, thus saving time and enhancing the discovery of local insights.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.
PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies targeting p53 mutations in cancer. The company's lead candidate, PC14586, aims to correct and restore the function of p53, a critical tumor suppressor protein. In addition to this product, PMV Pharmaceuticals is also working on therapies for specific p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, the company leverages over three decades of expertise in p53 biology, aiming to develop first-in-class modulators that could improve treatment outcomes for cancer patients.
Palmetto Moon is provides online apparel and accessories. It offers shirts, t-shirts, jackets, vests, sunglasses, and footwear for men, women, and children. Palmetto Moon serves customers in the United States
Texas Family Fitness provides a family-friendly environment complemented with state-of-the-art equipment and knowledgeable, friendly staff. Our clubs have the best workout floors available without charging members for amenities they don’t use. The end result is a family membership that costs less than a single membership at our local area competitors. We recognize the importance of creating a healthy atmosphere for the entire family at an affordable cost. Texas Family Fitness delivers the fitness experience done right.
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.
Polder is a manufacturer of housewares products. They offer products that include kitchen, bathroom, laundry, cooking, baking, grilling, sinkware, and storage.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.
JD Beauty Group is the perfect company to ensure that you are on the top of your beauty products game. Their product quality, selection, diversity, and prices are the best in the industry. They are commited to using only the best materials in concert with the finest craftsmanship.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.
ThermoLift is developing a disruptive and transformational thermally driven heat pump for heating cooling and hot water in one device. Based upon proven technology, ThermoLift expects to reduce commercial / residential space conditioning energy consumption by up to 50%.
SynchroPET Inc., founded in 2013 and based in Stony Brook, New York, specializes in developing innovative Positron Emission Tomography (PET) imaging systems tailored for both research and clinical applications. The company's product lineup includes PET/MRI systems designed for comprehensive preclinical research, Mini-PET, a portable imaging device for laboratory use, RatCAP, a buoyant device that allows for unhindered animal movement during imaging, and the Wrist PET Detector, a non-invasive scanner for clinical use. These advanced devices aim to enhance diagnostic accuracy and treatment potential for diseases such as cancer, Alzheimer's, and Parkinson's, by providing high-resolution imaging and quantitative data that facilitate personalized medical treatments and accelerate research in biomedical fields.
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.
PlayMonster is a prominent designer, manufacturer, and marketer of games, puzzles, and toys for children, adults, and families. The company specializes in creating a diverse range of products, including preschool toys, creative activities, and educational tools. With a strong emphasis on innovation, PlayMonster aims to grow its brands and expand its product categories, ensuring a broad appeal to various age groups and interests. Through its commitment to quality and creativity, PlayMonster has established itself as a key player in the toy and game industry.
Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.
Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.
Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.
Passport Systems Inc. specializes in designing and developing advanced inspection and detection systems aimed at addressing security threats, particularly in the wake of the 9/11 attacks. Founded in 2002 and headquartered in Billerica, Massachusetts, the company provides both active and passive solutions for the automatic detection, localization, and identification of concealed threats and contraband. Its product offerings include SmartScan 3D, a fixed cargo scanner that facilitates the automated clearance of non-threat cargo while detecting complex threats, and SmartShield, a networked radiation detection system focused on identifying radiological threats. These systems are utilized at various critical locations, such as airports, seaports, and border crossings, to enhance national and international security, ensure manifest verification, and monitor real-time radiation threats, thereby protecting urban populations and large events.
Neopolitan Networks, headquartered in Palo Alto, California, serves a broad clientele of small, medium-sized, and large organizations with scalable, flexible, robust networking solutions. They provide organizations with transport, including end-to-end private network solutions, Internet connectivity and robust points-of-presence in our data centers that capitalize on advances in fiber optic and wireless technologies to increase network performance and coverage.
Pionetics is an innovative water technology company that develops smart water treatment products that produce great tasting, safe drinking water with less wastewater than traditional water treatment systems. Pionetics is privately owned and financially backed by Kline Hawkes & Co, NGEN Partners, and Unilever Technology Ventures Fund.
Passport Systems Inc. specializes in designing and developing advanced inspection and detection systems aimed at addressing security threats, particularly in the wake of the 9/11 attacks. Founded in 2002 and headquartered in Billerica, Massachusetts, the company provides both active and passive solutions for the automatic detection, localization, and identification of concealed threats and contraband. Its product offerings include SmartScan 3D, a fixed cargo scanner that facilitates the automated clearance of non-threat cargo while detecting complex threats, and SmartShield, a networked radiation detection system focused on identifying radiological threats. These systems are utilized at various critical locations, such as airports, seaports, and border crossings, to enhance national and international security, ensure manifest verification, and monitor real-time radiation threats, thereby protecting urban populations and large events.
Game Trust, Inc. is a company focused on providing infrastructure for community and commerce applications within the online gaming and entertainment sectors. Founded in 2002 and headquartered in New York, it develops the Game Frame platform, which is tailored for online casual games. This platform allows website operators and game developers to enhance user experiences by integrating community features and commerce capabilities into both new and existing games. Game Trust serves a diverse clientele of game distributors and developers across the United States and Europe, facilitating a more engaging online entertainment environment. As of 2007, Game Trust operates as a subsidiary of RealNetworks, Inc.
Sensicore, Inc., based in Ann Arbor, Michigan, specializes in developing smart sensor systems and sensor networks for automated water testing, data collection, and analysis in both drinking and industrial applications. The company provides a range of products including WaterPOINT, a handheld device that offers various chemistry measurements for on-site testing, and WaterNOW, a web-based platform for data visualization and management. Additionally, Sensicore offers sensor kits and bundles for disinfection and basic water testing, as well as colorimetric test kits for a variety of water quality parameters. Their offerings are designed to support municipalities and industries in monitoring and managing water quality effectively. Founded in 2000, Sensicore operates as a subsidiary of GE Analytical Instruments, Inc.
Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for the treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for the treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.
Game Trust, Inc. is a company focused on providing infrastructure for community and commerce applications within the online gaming and entertainment sectors. Founded in 2002 and headquartered in New York, it develops the Game Frame platform, which is tailored for online casual games. This platform allows website operators and game developers to enhance user experiences by integrating community features and commerce capabilities into both new and existing games. Game Trust serves a diverse clientele of game distributors and developers across the United States and Europe, facilitating a more engaging online entertainment environment. As of 2007, Game Trust operates as a subsidiary of RealNetworks, Inc.
netomat, Inc. specializes in developing websites, applications, and social media services that function seamlessly across various devices, including desktops, tablets, and smartphones. The company offers a range of mobile solutions, such as responsive website design, mobile applications, and location-based services. It also provides web solutions, including websites, microsites, and web applications, alongside social media solutions that facilitate integration with social platforms and offer analytics, contests, and engagement tools. Additionally, netomat delivers creative services focused on user interface and experience design, as well as managed services encompassing cloud hosting, search engine optimization, and e-commerce integration. Its flagship Mobility Server enables organizations to publish web content across numerous mobile devices, while the MediaHub service allows for the management and streaming of video content. Catering to clients in diverse sectors, such as tourism, sports, and entertainment, netomat has established itself as a comprehensive provider of mobile web experience and content management solutions since its founding in 2001. The company is headquartered in New York, New York.
comScore, Inc. is an information and analytics company that specializes in measuring audiences, consumer behavior, and advertising across various media platforms globally. The company provides a range of ratings and planning products, including Media Metrix and Mobile Metrix for measuring website and app usage, Video Metrix for assessing digital video consumption alongside TV metrics, and Plan Metrix for understanding consumer lifestyles. Additionally, it offers validated Campaign Essentials (vCE) to ensure digital ad visibility and audience targeting, as well as Campaign Ratings for comprehensive campaign evaluation across platforms. Its services also include TV Essentials, StationView Essentials, and OnDemand Essentials, which analyze viewing patterns and transactional data. Furthermore, comScore delivers analytics for the film industry, measuring movie viewership and box office performance in real-time. Founded in 1999 and based in Reston, Virginia, comScore combines extensive digital, TV, and movie intelligence, helping over 3,200 clients worldwide optimize their advertising efforts and audience engagement.
Sensicore, Inc., based in Ann Arbor, Michigan, specializes in developing smart sensor systems and sensor networks for automated water testing, data collection, and analysis in both drinking and industrial applications. The company provides a range of products including WaterPOINT, a handheld device that offers various chemistry measurements for on-site testing, and WaterNOW, a web-based platform for data visualization and management. Additionally, Sensicore offers sensor kits and bundles for disinfection and basic water testing, as well as colorimetric test kits for a variety of water quality parameters. Their offerings are designed to support municipalities and industries in monitoring and managing water quality effectively. Founded in 2000, Sensicore operates as a subsidiary of GE Analytical Instruments, Inc.
Pionetics is an innovative water technology company that develops smart water treatment products that produce great tasting, safe drinking water with less wastewater than traditional water treatment systems. Pionetics is privately owned and financially backed by Kline Hawkes & Co, NGEN Partners, and Unilever Technology Ventures Fund.
comScore, Inc. is an information and analytics company that specializes in measuring audiences, consumer behavior, and advertising across various media platforms globally. The company provides a range of ratings and planning products, including Media Metrix and Mobile Metrix for measuring website and app usage, Video Metrix for assessing digital video consumption alongside TV metrics, and Plan Metrix for understanding consumer lifestyles. Additionally, it offers validated Campaign Essentials (vCE) to ensure digital ad visibility and audience targeting, as well as Campaign Ratings for comprehensive campaign evaluation across platforms. Its services also include TV Essentials, StationView Essentials, and OnDemand Essentials, which analyze viewing patterns and transactional data. Furthermore, comScore delivers analytics for the film industry, measuring movie viewership and box office performance in real-time. Founded in 1999 and based in Reston, Virginia, comScore combines extensive digital, TV, and movie intelligence, helping over 3,200 clients worldwide optimize their advertising efforts and audience engagement.
TeraLogic designs integrated circuits, software and platforms for digital TV.